Company Overview

We are committed to developing novel therapeutics for agitation and pain

Our Mission

Developing innovative therapeutics targeting inflammatory signalling pathways in the nervous system to address major unmet needs in CNS disorders.

“We work with urgency to support the millions of patients and their loved ones who are suffering from agitation and pain.”

– Hugh Alsop, CEO Kinoxis

Who are we?

Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics targeting ALOX15, a key regulator of neuroinflammation and neural excitability in the brain. By modulating disease-relevant biological pathways, Kinoxis is advancing mechanism-based precision therapies to treat agitation, aggression, pain, and substance use disorders, with the goal of improving patient outcomes and quality of life.

Kinoxis’ lead clinical candidate, KNX100, is a first-in-class, short-acting small-molecule inhibitor of ALOX15 being developed for the treatment of acute agitation and aggression associated with dementia and other neuropsychiatric conditions. The compound is currently being evaluated in the CARES-X Phase 2 clinical study.

In parallel, Kinoxis is developing KNX101, a second-generation, long-acting ALOX15 inhibitor designed to address acute and chronic pain, as well as chronic agitation, through sustained modulation of neuroinflammatory signaling pathways. These programs form part of Kinoxis’ broader strategy to deliver novel, non-opioid and non-sedating therapies for patients with significant unmet medical needs.

Find out about our latest clinical trials